Tag Archives: USPTO

The Return Of The Magnificent Prosecution Specialists Or Just More “QA”?

Posted on April 15, 2010 by Warren Woessner

The USPTO recently announced the creation of an ombudsman program to resolve applicant/examiner logjams in all of the Tech Centers. This is a move that the Office (and practitioners) have needed badly for a number of years, ever since the … Continue reading →

Posted in USPTO Practice and Policy | Tagged biotechnology law, intellectual property, ip, Patent Law, USPTO, Warren Woessner | Leave a comment

Myriad Ruling: DNA Sequences Are Unpatentable “ Products Of Nature”

Posted on March 30, 2010 by Warren Woessner

In a lengthy opinion released yesterday in Assoc. for Molec. Pathology v. USPTO, __F.Supp.2d___(S.D. N.Y.) (PDF below), the court invalidated claims directed to isolated DNA sequences, as well as to cancer screening methods using them, and even to methods of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged biotechnology, biotechnology law, DNA, Myriad, Myriad lawsuit, Patent Law, USPTO, Warren Woessner | 1 Comment

PTO Biotech/Chem/Pharma Customer Partnership Meeting Announced

Posted on February 18, 2010 by Warren Woessner

The USPTO has announced that it will hold a meeting of the Biotechnology/Chemical/Pharmaceutical Customer Partnership on Tuesday, March 2nd, in the Madison Auditorium of the USPTO in Alexandria, VA (agenda attached). You can attend in person or via a link … Continue reading →

Posted in USPTO Practice and Policy | Tagged biotechnology law, Patent Law, USPTO, Warren Woessner | Leave a comment

PTO “POINT SYSTEM” DISTRIBUTED

Posted on February 16, 2010 by Warren Woessner

I thought it worthwhile to post this “point system,” since I had never seen one before. It is encouraging that the highest tier of points an Examiner can achieve is a first office action allowance, but a little discouraging that … Continue reading →